pretomanid
Selected indexed studies
- Pretomanid. (, 2012) [PMID:31869193]
- Pretomanid: First Approval. (Drugs, 2019) [PMID:31583606]
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. (N Engl J Med, 2022) [PMID:36053506]
_Worker-drafted node — pending editorial review._
Connections
pretomanid is a side effect of
Sources
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. (2022) pubmed
- Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. (2025) pubmed
- Pretomanid. (2012) pubmed
- Pretomanid: First Approval. (2019) pubmed
- Pretomanid for tuberculosis: a systematic review. (2022) pubmed
- Pretomanid. (2006) pubmed
- Pretomanid: The latest USFDA-approved anti-tuberculosis drug. (2021) pubmed
- Pretomanid development and its clinical roles in treating tuberculosis. (2022) pubmed
- Pretomanid-resistant tuberculosis. (2023) pubmed
- Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. (2023) pubmed